Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gossamer Bio Inc (NQ: GOSS )

0.6958 +0.0312 (+4.69%)
Streaming Delayed Price Updated: 1:48 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Gossamer Bio Inc

< Previous 1 2 Next >
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Gossamer Bio, Inc.
Via Business Wire
Gossamer Bio Announces Third Quarter 2024 Financial Results and Provides Business Update
From Gossamer Bio, Inc.
Via Business Wire
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Gossamer Bio, Inc.
Via Business Wire
Gossamer Bio Announces Data Presentations at the European Respiratory Society Congress 2024
From Gossamer Bio, Inc.
Via Business Wire
Gossamer Bio Announces Second Quarter 2024 Financial Results and Provides Business Update
From Gossamer Bio, Inc.
Via Business Wire
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Gossamer Bio, Inc.
Via Business Wire
Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference
From Gossamer Bio, Inc.
Via Business Wire
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Gossamer Bio, Inc.
Via Business Wire
Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update
From Gossamer Bio, Inc.
Via Business Wire
Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications
From Gossamer Bio, Inc.
Via Business Wire
Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine
From Gossamer Bio, Inc.
Via Business Wire
Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors
From Gossamer Bio, Inc.
Via Business Wire
Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
From Gossamer Bio, Inc.
Via Business Wire
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Gossamer Bio, Inc.
Via Business Wire
Gossamer Bio to Host Webcast to Discuss Latest Seralutinib Open-Label Extension Data on December 18, 2023
From Gossamer Bio, Inc.
Via Business Wire
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Gossamer Bio, Inc.
Via Business Wire
Gossamer Bio Appoints Bob Smith as Chief Commercial Officer
From Gossamer Bio, Inc.
Via Business Wire
Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of Directors
From Gossamer Bio, Inc.
Via Business Wire
Gossamer Bio Announces Third Quarter 2023 Financial Results and Provides Business Update
From Gossamer Bio, Inc.
Via Business Wire
Gossamer Bio Announces Addition of Rainer Zimmermann, MD, as VP of Medical Affairs
From Gossamer Bio, Inc.
Via Business Wire
Gossamer Bio to Present Results of TORREY FRI Sub-Study at the European Respiratory Society International Congress 2023
From Gossamer Bio, Inc.
Via Business Wire
Gossamer Bio Announces Second Quarter 2023 Financial Results and Provides Business Update
From Gossamer Bio, Inc.
Via Business Wire
Gossamer Bio to Hold Conference Call with PAH Experts to Discuss PROSERA Phase 3 Design and Interim TORREY OLE Results
From Gossamer Bio, Inc.
Via Business Wire
Gossamer Bio Announces $212 Million Private Placement Financing
From Gossamer Bio, Inc.
Via Business Wire
Gossamer Bio Announces TORREY Data to be Featured at American Thoracic Society 2023 International Conference
From Gossamer Bio, Inc.
Via Business Wire
Gossamer Bio Announces First Quarter 2023 Financial Results and Provides Business Update
From Gossamer Bio, Inc.
Via Business Wire
Gossamer Bio Announces Fourth Quarter and Full-Year 2022 Financial Results and Provides Business Update
From Gossamer Bio, Inc.
Via Business Wire
Gossamer Bio Announces Seralutinib Meets Primary Endpoint in Phase 2 TORREY Study in PAH
From Gossamer Bio, Inc.
Via Business Wire
Gossamer Bio Announces Third Quarter 2022 Financial Results and Provides Business Update
From Gossamer Bio, Inc.
Via Business Wire
Gossamer Bio Announces Second Quarter 2022 Financial Results and Provides Business Update
From Gossamer Bio, Inc.
Via Business Wire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.